2.27 (-%)
As of Nov 29, 2024
Source:
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death.
Country | United States |
Headquarters | charlottesville, virginia |
Phone Number | (434) 297-1000 |
Industry | manufacturing |
CEO | Daniel O’Connell |
Website | www.acumenpharm.com |